ReviewMedComm2025
Phage and Endolysin Therapy Against Antibiotics Resistant Bacteria: From Bench to Bedside.
Review in MedComm, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Bacteriophages in the treatment of cutaneous infections and skin disorders: therapeutic advances and future directions.Clinical microbiology reviews · 2026Review
- Development and clinical validation of a CRISPR/Cas9-engineered reporter phage cocktail for rapid detection ofMicrobiology spectrum · 2026Article
- Antibacterial Efficacy of Recombinant Endolysin S.AgEndo1332 in Combination with Antibiotics against Mastitis-Associated S. aureus in a Mouse Mastitis Model.Probiotics and antimicrobial proteins · 2026Article
- Beyond the Barrier: Overcoming Ocular Antimicrobial Resistance Through AI and Novel Therapeutics.International journal of molecular sciences · 2026Review
- Liposome-Mediated Bacterial Ferroptosis-like Death: A Novel Paradigm for Antimicrobial Therapy.Antibiotics (Basel, Switzerland) · 2026Review
- Phage-Derived Endolysins TargetingAntibiotics (Basel, Switzerland) · 2026Review
- Role of MexAB-OprM and MexXY-OprM efflux pumps in carbapenem-resistant Pseudomonas aeruginosa from burn wounds.Molecular biology reports · 2026Article
- Article
- Efficacy of a novel bacteriophage in controlling Escherichia coli associated with swine farm environments and its potential for biofilm disruption.Scientific reports · 2026Article
- Enzyme therapy as a promising strategy to overcome multi-drug resistance in pathogens: current advances, key challenges, and future directions.RSC advances · 2026Review
- Bovine Mastitis Therapy at a Crossroads: Pharmacokinetic Barriers, Biofilms, Antimicrobial Resistance, and Emerging Solutions.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Phage-quinolone synergy: mechanisms, clinical strategies, and translational prospects.Frontiers in microbiology · 2026Review
- Antimicrobial efficacy and cytotoxic assessment of plasma-activated water generated by a dielectric barrier discharge microbubble system.Frontiers in microbiology · 2026Article
- Experimental screening and structure-informed engineering of peptide-fused bacteriophage lysins with enhanced activity against Gram-negative bacteria.Frontiers in pharmacology · 2026Article
- Bacteriophages targetingFrontiers in microbiology · 2026Review
- Translational barriers to phage endolysin deployment for antimicrobial resistance control in Africa.Frontiers in antibiotics · 2026Review
- PEGylation Overcomes Pharmacological Barriers to Improve Systemic Pharmacokinetics and Therapeutic Efficacy of Phages against MDRJournal of microbiology and biotechnology · 2025Article
- Phage Encapsulation and Delivery Technology: A Strategy for Treating Drug-Resistant Pathogenic Microorganisms.Pharmaceuticals (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The rapid global spread of antibiotic-resistant bacteria presents a growing public health crisis, threatening the efficacy of existing antimicrobial treatments. As traditional antibiotics become increasingly ineffective, alternative therapies such as bacteriophages and endolysins have gained renewed scientific and clinical interest. These biological agents, naturally derived from bacteriophage life cycles, exhibit potent and selective antibacterial activity, especially against multidrug-resistant pathogens. Despite decades of research, the clinical translation of phage and endolysin therapies remains limited due to regulatory, delivery, and stability challenges. This review provides a comprehensive overview of the mechanisms, advantages, and limitations of both bacteriophages and endolysins, including their structure, mode of action, and interaction with bacterial hosts. Particular attention is given to combination therapies, where synergistic effects have been observed-especially in biofilm-associated infections. We also explore the latest findings from preclinical studies, clinical trials, and compassionate-use cases, with an emphasis on genetically engineered and synthetic variants that enhance therapeutic potential. Furthermore, we discuss manufacturing challenges, regulatory barriers, and future directions such as personalized phage therapy and engineered endolysins. By synthesizing current knowledge, this review highlights the academic and translational significance of phage and endolysin-based approaches in combating antibiotic-resistant infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.